Compare Gilead Sciences, Inc. (GILD) vs Hut 8 Corp (HUT) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

HUT's stock is trading at $90.45, down 8.01% over the past 24 hours amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though recent earnings have shown volatility with a mix of beats and misses. Positive developments include a strategic pivot to AI infrastructure, securing $16.8 billion in contracted revenue, and strong analyst support with a 93.75% buy rating.

The outlook is a balance of high growth potential from its AI data center expansion against significant execution risks and persistent profitability challenges. The consensus price target of $138.89 implies substantial upside if the company successfully monetizes its infrastructure investments, but investors face risks from high debt levels, competitive pressures, and reliance on future project success.